A Phase 1, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 Following Multiple-Ascending Dose Administration in Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 29 Jun 2018
At a glance
- Drugs AZD 9977 (Primary)
- Indications Diabetic nephropathies
- Focus Adverse reactions
- Sponsors AstraZeneca
- 20 Jun 2018 Status changed from active, no longer recruiting to completed.
- 05 Jun 2018 Planned End Date changed from 7 Jun 2018 to 5 Jun 2018.
- 05 Jun 2018 Planned primary completion date changed from 7 Jun 2018 to 5 Jun 2018.